• Home Blog Tag Immune thrombocytopenia treatment market

Immune Thrombocytopenia Treatment Market

Sep 02, 2025

FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s; Travere Therapeutics Gains FDA Nod for FILSPARI REMS Update in IgA Nephropathy; Vanda Pharmaceuticals’ VGT-1849B Granted FDA Orphan Drug Status for Polycythemia Vera; Teva Launches First FDA-Approved Generic SAXENDA for Weight Loss; Sanofi’s WAYRILZ Gets FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

Apr 30, 2024

X4 Pharmaceuticals’ XOLREMDI FDA Approval; ONO to Acquire Deciphera Pharmaceuticals; Johnson & Johnson’s SIRTURO CHMP Approval; BeiGene’s Tislelizumab EC Approval; Sanofi’s Rilzabrutinib LUNA 3 Phase III Trial

Jan 22, 2021

Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market?

May 25, 2020

R&D and Upcoming therapies Paving the Way for a Potential and Better Cure for Immune Thrombocytopenia

Newsletter/Whitepaper